Cargando…
PD‐L1 expression on tumor or stromal cells of nodal cytotoxic T‐cell lymphoma: A clinicopathological study of 50 cases
Inhibitors of programmed cell‐death 1 (PD‐1) and programmed cell‐death ligand 1 (PD‐L1) have revolutionized cancer therapy. Nodal cytotoxic T‐cell lymphoma (CTL) is characterized by a poorer prognosis compared to nodal non‐CTLs. Here we investigated PD‐L1 expression in 50 nodal CTL patients, with an...
Autores principales: | Yamashita, Daisuke, Shimada, Kazuyuki, Kohno, Kei, Kogure, Yasunori, Kataoka, Keisuke, Takahara, Taishi, Suzuki, Yuka, Satou, Akira, Sakakibara, Ayako, Nakamura, Shigeo, Asano, Naoko, Kato, Seiichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496983/ https://www.ncbi.nlm.nih.gov/pubmed/32424876 http://dx.doi.org/10.1111/pin.12950 |
Ejemplares similares
-
Reappraisal of nodal Epstein‐Barr Virus‐negative cytotoxic T‐cell lymphoma: Identification of indolent CD5(+) diseases
por: Yamashita, Daisuke, et al.
Publicado: (2018) -
Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review
por: Sakakibara, Ayako, et al.
Publicado: (2021) -
PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy
por: Suzuki, Yuka, et al.
Publicado: (2020) -
Lymphocyte-depleted classic Hodgkin lymphoma with primary extranodal disease:
Two cases that highlight the combination of immunodeficiency and immune escape in the
pathogenesis
por: Tsuyuki, Yuta, et al.
Publicado: (2021) -
Clinicopathological analysis of primary intestinal diffuse large B‐cell lymphoma: Prognostic evaluation of CD5, PD‐L1, and Epstein‐Barr virus on tumor cells
por: Ishikawa, Eri, et al.
Publicado: (2018)